CNS Metastases in EGFR-Mutated NSCLC: Interpreting Intracranial Efficacy Data and Implications for Treatment Selection

Dr. Riess addresses the high rate of CNS metastasis development in EGFR-mutated NSCLC (25%-45%), noting that MARIPOSA's requirement for serial brain MRIs in all participants generated robust intracranial efficacy data. Dr. Gumbleton explains that he does not substantially differentiate his frontline treatment approach based on the presence or absence of brain metastases at diagnosis, because EGFR-mutated NSCLC has high CNS tropism regardless of baseline CNS status. He illustrates this with a clinical observation of a patient who developed 16 brain metastases and leptomeningeal involvement on osimertinib monotherapy, underscoring the importance of proactive treatment intensification.

On the question of intracranial benefit with amivantamab, a large molecule antibody, Dr. Gumbleton offers three mechanisms: disruption of the blood-brain barrier in patients with established brain metastases may permit large molecule penetration; improved systemic disease control may secondarily reduce CNS seeding; and preemptive MET blockade may prevent cancer cells from acquiring MET amplification, a mechanism associated with aggressive tumor biology and potential CNS progression.

Comparing the intracranial PFS data from MARIPOSA (hazard ratio 0.69 with brain metastases) and FLAURA2 (hazard ratio 0.56), Dr. Gumbleton favors amivantamab-lazertinib for its more durable intracranial response shape over time, while also noting the strategic value of preserving platinum-based chemotherapy for later treatment lines. Preserving chemotherapy provides a meaningful inpatient option at progression, and potentially enables future combinations with emerging agents such as ivonesimab if approved. He acknowledges this involves extrapolation given the absence of a head-to-head comparison between the two intensified regimens.